Towards treatment of asthma

致力于治疗哮喘

• 批准号: nhmrc : 1075962
• 负责人: A/Pr Mark Smythe
• 金额: $ 22.56万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/treatment-asthma/455706
• 关键词: Towards; treatment; asthma

Prostaglandin D2 (PGD2) is a key driver of asthma and allergic rhinitis. We have developed drug-like compounds that block the synthesis of PGD2 by inhibiting the hematopoietic prostaglandin D2 synthase (HPGD2S) enzyme. This project aims to develop these compounds further to ultimately treat a subset of the asthma population that are not well treated, refractory asthmatics.

前列腺素D2（PGD2）是哮喘和过敏性鼻炎的关键驱动因素。我们已经开发了药物样化合物，通过抑制造血前列腺素D2合成酶（HPGD 2S）来阻断PGD 2的合成。该项目旨在进一步开发这些化合物，以最终治疗未得到良好治疗的哮喘人群，难治性哮喘患者。